{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:16:32Z","timestamp":1783397792833,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ctro.2026.101161","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T17:08:11Z","timestamp":1775495291000},"page":"101161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Oncological outcomes following PSMA PET\/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7392-1626","authenticated-orcid":false,"given":"L.G.","family":"Zuur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"van der Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6892-8943","authenticated-orcid":false,"given":"K.C.C.","family":"de Bie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.E.","family":"Schaake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0903-4149","authenticated-orcid":false,"given":"F.J.","family":"Pos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4992-8024","authenticated-orcid":false,"given":"W.V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101161_b0005","doi-asserted-by":"crossref","unstructured":"Vernooij RW, Lancee M, Cleves A, et al. Radical prostatectomy versus deferred treatment for localised prostate cancer. Cochrane Database Syst Rev. 2020;6(6):CD006590.","DOI":"10.1002\/14651858.CD006590.pub3"},{"issue":"1","key":"10.1016\/j.ctro.2026.101161_b0010","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1590\/s1677-5538.ibju.2016.0656","article-title":"Biochemical recurrence after radical prostatectomy: what does it mean?","volume":"44","author":"Tourinho-Barbosa","year":"2018","journal-title":"Int Braz J Urol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101161_b0015","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101161_b0020","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.eururo.2025.03.003","article-title":"A comprehensive systematic review and meta-analysis of the role of prostate-specific membrane antigen positron emission tomography for prostate cancer diagnosis and primary staging before definitive treatment","volume":"87","author":"Mazzone","year":"2025","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.ctro.2026.101161_b0030","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1007\/s00259-020-04809-8","article-title":"(68)Ga-PSMA-11 PET\/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapy","volume":"47","author":"Deandreis","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"10.1016\/j.ctro.2026.101161_b0035","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/iju.14012","article-title":"How does (68) Ga-prostate-specific membrane antigen positron emission tomography\/computed tomography impact the management of patients with prostate cancer recurrence after surgery?","volume":"26","author":"Bianchi","year":"2019","journal-title":"Int J Urol"},{"key":"10.1016\/j.ctro.2026.101161_b0040","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"issue":"11","key":"10.1016\/j.ctro.2026.101161_b0045","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ctro.2026.101161_b0050","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2026.101161_b0055","unstructured":"Services USDoHaH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Cancer Institute. 2017."},{"issue":"2","key":"10.1016\/j.ctro.2026.101161_b0060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.ctro.2026.101161_b0065","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.ctro.2026.101161_b0025","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ctro.2026.101161_b0070","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bju.13679","article-title":"Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy","volume":"119","author":"Tilki","year":"2017","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ctro.2026.101161_b0075","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctro.2026.101161_b0080","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","article-title":"Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies","volume":"73","author":"Touijer","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ctro.2026.101161_b0085","doi-asserted-by":"crossref","unstructured":"Ventimiglia E, Seisen T, Abdollah F, et al. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. European Urology Oncology: Elsevier B.V.; 2019. p. 294-301.","DOI":"10.1016\/j.euo.2019.02.001"},{"issue":"4","key":"10.1016\/j.ctro.2026.101161_b0090","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00259-018-4203-0","article-title":"Clinical impact of (68)Ga-PSMA-11 PET on patient management and outcome, including all patients referred for an increase in PSA level during the first year after its clinical introduction","volume":"46","author":"Muller","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"15","key":"10.1016\/j.ctro.2026.101161_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153766","article-title":"Salvage nodal radiotherapy as metastasis-directed therapy for oligorecurrent prostate cancer detected by positron emission tomography shows favorable outcome in long-term follow-up","volume":"14","author":"Tamihardja","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.ctro.2026.101161_b0100","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-021-05557-z","article-title":"Outcome after PSMA-PET\/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy","volume":"49","author":"Rogowski","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ctro.2026.101161_b0105","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00259-018-4159-0","article-title":"Salvage extended field or involved field nodal irradiation in (18)F-fluorocholine PET\/CT oligorecurrent nodal failures from prostate cancer","volume":"46","author":"Lepinoy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ctro.2026.101161_b0110","unstructured":"De Bleser E, Alicja Jereczek-Fossa B, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy."},{"issue":"3","key":"10.1016\/j.ctro.2026.101161_b0115","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.euo.2023.09.007","article-title":"PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): acute toxicity of a randomized phase 2 trial","volume":"7","author":"Ost","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ctro.2026.101161_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2025.05.019","article-title":"Oncologic outcomes of template versus radioguided salvage lymph node dissection for node-only recurrent prostate cancer on prostate-specific membrane antigen positron emission tomography scan: results from a multi-institutional collaboration","author":"Bravi","year":"2025","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.ctro.2026.101161_b0125","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen\u2013radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101161_b0130","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctro.2026.101161_b0135","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bju.13926","article-title":"Natural history of 'second' biochemical failure after salvage radiation therapy for prostate cancer: a multi-institution study","volume":"121","author":"Tumati","year":"2018","journal-title":"BJU Int"},{"issue":"32","key":"10.1016\/j.ctro.2026.101161_b0140","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3 Pt 1","key":"10.1016\/j.ctro.2026.101161_b0145","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.juro.2016.08.106","article-title":"Very early salvage radiotherapy improves distant metastasis-free survival","volume":"197","author":"Abugharib","year":"2017","journal-title":"J Urol"},{"issue":"10338","key":"10.1016\/j.ctro.2026.101161_b0150","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"10442","key":"10.1016\/j.ctro.2026.101161_b0155","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.ctro.2026.101161_b0160","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2217\/fon-2020-0390","article-title":"Long- versus short-term androgen deprivation therapy with high-dose radiotherapy for biochemical failure after radical prostatectomy: a randomized controlled trial","volume":"16","author":"Berghen","year":"2020","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.ctro.2026.101161_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5306\/wjco.v11.i1.1","article-title":"Are all prostate cancer patients \u201cfit\u201d for salvage radiotherapy?","volume":"11","author":"Gonzalez-San Segundo","year":"2020","journal-title":"World J Clin Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240563082600056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T03:39:28Z","timestamp":1783395568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240563082600056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":33,"alternative-id":["S240563082600056X"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101161","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological outcomes following PSMA PET\/CT-guided salvage whole-pelvis radiotherapy for recurrent prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101161","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101161"}}